Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Alder Biopharma (ALDR)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 980,235
  • Shares Outstanding, K 68,500
  • Annual Sales, $ 0 K
  • Annual Income, $ -296,430 K
  • 60-Month Beta 2.80
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 8.36

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate -1.16
  • Number of Estimates 5
  • High Estimate -1.10
  • Low Estimate -1.21
  • Prior Year -1.73
  • Growth Rate Est. (year over year) +32.95%

Price Performance

See More
Period Period Low Period High Performance
1-Month
11.82 +9.56%
on 02/27/19
14.95 -13.38%
on 02/25/19
-1.40 (-9.76%)
since 02/22/19
3-Month
9.44 +37.18%
on 12/24/18
15.17 -14.63%
on 01/31/19
+3.15 (+32.14%)
since 12/21/18
52-Week
9.44 +37.18%
on 12/24/18
20.87 -37.95%
on 08/08/18
+1.60 (+14.10%)
since 03/22/18

Most Recent Stories

More News
Relatively Good Performance Detected in Shares of Karyopharm Thera in the Biotechnology Industry (KPTI , VCYT , ALDR , NBIX , RDUS )

We looked at the Biotechnology industry and measured relative performance to find the top stocks. Relative outperformance is a bullish sign of underlying fundamental and technical strength. We look at...

VCYT : 24.46 (+1.24%)
ALDR : 12.95 (-9.50%)
KPTI : 5.44 (-6.53%)
Menlo Therapeutics Announces New Board Member Elisabeth Sandoval

Menlo Therapeutics Inc. (NASDAQ: MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus (itch), today announced that Elisabeth Sandoval has...

MNLO : 7.76 (-1.40%)
ALDR : 12.95 (-9.50%)
Alder BioPharmaceuticals(R) to Present at the Cowen and Company 39th Annual Health Care Conference

Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today announced that Bob Azelby, Alder's president...

ALDR : 12.95 (-9.50%)
Alder BioPharmaceuticals, Inc. Announces Closing of Public Offering and Private Placement of Common Stock and Exercise in Full of Option to Purchase Additional Shares

Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, announced today the closing of its previously...

ALDR : 12.95 (-9.50%)
Recent Analysis Shows McDermott International, Nu Skin Enterprises, Marcus, Keysight Technologies, Alder BioPharmaceuticals, and LendingTree Market Influences -- Renewed Outlook, Key Drivers of Growth

In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of McDermott International, Inc. (NYSE:MDR),...

KEYS : 84.76 (-3.16%)
ALDR : 12.95 (-9.50%)
TREE : 330.64 (-3.16%)
MDR : 7.03 (-5.64%)
MCS : 38.83 (-2.61%)
NUS : 49.28 (-4.99%)
Alder Biopharmac Has Returned 15.8% Since SmarTrend Recommendation (ALDR)

SmarTrend identified an Uptrend for Alder Biopharmac (NASDAQ:ALDR) on January 7th, 2019 at $11.65. In approximately 2 months, Alder Biopharmac has returned 15.79% as of today's recent price of $13.49....

ALDR : 12.95 (-9.50%)
Alder BioPharmaceuticals(R) Reports Fourth Quarter and Full Year 2018 Financial and Operating Results

- Completes eptinezumab's Biologics License Application (BLA) submission -

ALDR : 12.95 (-9.50%)
Alder Biopharmaceuticals, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / February 25, 2019 / Alder Biopharmaceuticals, Inc. (NASDAQ: ) will be discussing their earnings results in their 2018 Fourth Quarter Earnings to be held on February 25, 2019...

ALDR : 12.95 (-9.50%)
Alder BioPharmaceuticals(R) Submits Biologics License Application to the U.S. Food and Drug Administration for Eptinezumab

Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today announced it has submitted a Biologics...

ALDR : 12.95 (-9.50%)
Alder BioPharmaceuticals(R) to Present at the 8th Annual SVB Leerink Global Healthcare Conference

Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today announced that Bob Azelby, Alder's president...

ALDR : 12.95 (-9.50%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum. Long term indicators fully support a continuation of the trend.

See More Share

Trade ALDR with:

Business Summary

Alder Biopharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It discovers, develops and seeks to commercialize therapeutic antibodies. It is developing monoclonal antibodies comprising ALD403, for the prevention of migraine; and Clazakizumab, in the treatment of rheumatoid arthritis and...

See More

Key Turning Points

2nd Resistance Point 14.68
1st Resistance Point 13.82
Last Price 12.95
1st Support Level 12.48
2nd Support Level 12.00

See More

52-Week High 20.87
Fibonacci 61.8% 16.50
Fibonacci 50% 15.15
Fibonacci 38.2% 13.81
Last Price 12.95
52-Week Low 9.44

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar